NCT01881217View on ClinicalTrials.gov

First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

June 28, 2013

Primary Completion Date

March 18, 2016

Study Completion Date

August 16, 2016

Conditions

Neoplasms

Interventions

DRUG

BAY1179470

BAY1179470 will be administered as a 1-hour intravenous infusion.

Trial Locations (8)

119074

Singapore

169610

Singapore

277-8577

Kashiwa

362-0806

Kita-Adachigun

104-0045

Chuo-ku

135-8550

Koto-ku

811-1395

Fukuoka

138-736

Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY